Macquarie Names Five Taiwan AI Stocks Set to Benefit From Data Center Growth in 2026 
OpenAI Expands Globally with First Overseas AI Lab in Singapore 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Toshifumi Suzuki, Founder of Seven-Eleven Japan, Dies at 93 
GameStop Raises eBay Stake to 6.6% as Ryan Cohen Pushes $56 Billion Takeover Bid 
Samsung Union Confirms 18-Day Strike After Failed Wage Talks 
Morgan Stanley Names Top AI Security and Data Center Stocks for 2026 
Meta AI Push Could Add $26 Billion in Revenue by 2027, Wolfe Research Says 
SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Intuit Raises Full-Year Forecast After Strong Q3 Earnings Despite Stock Drop 
H.B. Fuller Eyes Advanced Medical Solutions in Potential £600M Takeover Deal 
Nvidia Beats Earnings Expectations as AI Demand Drives Record Growth 
Google Expands AI Partnership With Singapore Government 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
Ferrari Luce: How Ferrari Evolved From Hybrid Supercars to Its First Fully Electric Vehicle 
PDG Explores $1 Billion Sale of China Data Center Assets 
 and Lead Plaintiff Deadline - March 13, 2017 - EconoTimes)
NEW YORK, Feb. 02, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Novo Nordisk A/S ("Novo" or the "Company") (NYSE:NVO) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased Novo American Depositary Receipts ("ADR") between April 30, 2015 and October 27, 2016, both dates inclusive (the “Class Period”). Investors with losses in excess of $1 million are advised to join this case by visiting the firm’s site: http://www.bgandg.com/nvo.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Novo reported materially false and misleading Company earnings and predications in that they were inflated through the collusive price fixing of Novo’s insulin drugs. The Complaint also alleges that Novo misrepresented and concealed the true extent of the pricing pressures it was experiencing from pharmacy benefit managers.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/nvo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. Investors with losses in excess of $1 million in Novo have until March 13, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
